(Q43821405)

English

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial (English)

1 reference

Europe PubMed Central

27 November 2017

anticoagulation

1 reference

based on heuristic

inferred from title

myocardial infarction

1 reference

based on heuristic

inferred from title

acute myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

1 reference

ORCID Public Data File 2021

Ian C. Marschner

1 reference

ORCID Public Data File 2021

author name string

H White

1

1 reference

Europe PubMed Central

27 November 2017

Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators

2

1 reference

Europe PubMed Central

27 November 2017

language of work or name

0 references

publication date

1 December 2001

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

358

1 reference

Europe PubMed Central

27 November 2017

9296

1 reference

Europe PubMed Central

27 November 2017

1855-1863

1 reference

Europe PubMed Central

27 November 2017

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation : An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of reteplase with alteplase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction; a phase II dose escalation, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906887-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(01)06887-8

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43821405&oldid=2103650396"